PTAB upholds Seer nanoparticle protein enrichment patent in Bruker challenge

Reuters03-30
PTAB upholds Seer nanoparticle protein enrichment patent in Bruker challenge
  • PTAB upheld key claims in U.S. Patent No. 11,435,360 covering Proteograph nanoparticle protein-enrichment methods in a challenge brought by Bruker subsidiaries PreOmics GmbH and Biognosys AG.
  • Final Written Decision dated March 23, 2026 left 23 claims valid, including five of 11 challenged claims.
  • Patent is owned by Brigham and Women’s Hospital and exclusively licensed to Seer.
  • Ruling preserves intellectual property protection for Proteograph-based deep proteomic analysis across multiple biological sample types.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603300700PRIMZONEFULLFEED9680486) on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment